Genome-scale CRISPR–Cas9 screen reveals novel regulators of B7-H3 in tumor cells

BACKGROUND: Despite advances in B7 homolog 3 protein (B7-H3) based immunotherapy, the development of drug resistance remains a major clinical concern. The heterogeneity and emerging loss of B7-H3 expression are the main causes of drug resistance and treatment failure in targeted therapies, which rev...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Shasha, Wang, Yuelong, Yang, Nian, Mu, Min, Wu, Zhiguo, Li, Hexian, Tang, Xin, Zhong, Kunhong, Zhang, Zongliang, Huang, Cheng, Cao, Ting, Zheng, Meijun, Wang, Guoqing, Nie, Chunlai, Yang, Hui, Guo, Gang, Zhou, Liangxue, Zheng, Xi, Tong, Aiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244714/
https://www.ncbi.nlm.nih.gov/pubmed/35768165
http://dx.doi.org/10.1136/jitc-2022-004875

Ejemplares similares

Ejemplares similares